APA
Kolinsky M. P., Rescigno P., Bianchini D., Zafeiriou Z., Mehra N., Mateo J., Michalarea V., Riisnaes R., Crespo M., Figueiredo I., Miranda S., Nava Rodrigues D., Flohr P., Tunariu N., Banerji U., Ruddle R., Sharp A., Welti J., Lambros M., Carreira S., Raynaud F. I., Swales K. E., Plymate S., Luo J., Tovey H., Porta N., Slade R., Leonard L., Hall E. & de Bono J. S. (20210106). A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.
Chicago
Kolinsky M P, Rescigno P, Bianchini D, Zafeiriou Z, Mehra N, Mateo J, Michalarea V, Riisnaes R, Crespo M, Figueiredo I, Miranda S, Nava Rodrigues D, Flohr P, Tunariu N, Banerji U, Ruddle R, Sharp A, Welti J, Lambros M, Carreira S, Raynaud F I, Swales K E, Plymate S, Luo J, Tovey H, Porta N, Slade R, Leonard L, Hall E and de Bono J S. 20210106. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.
Harvard
Kolinsky M. P., Rescigno P., Bianchini D., Zafeiriou Z., Mehra N., Mateo J., Michalarea V., Riisnaes R., Crespo M., Figueiredo I., Miranda S., Nava Rodrigues D., Flohr P., Tunariu N., Banerji U., Ruddle R., Sharp A., Welti J., Lambros M., Carreira S., Raynaud F. I., Swales K. E., Plymate S., Luo J., Tovey H., Porta N., Slade R., Leonard L., Hall E. and de Bono J. S. (20210106). A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.
MLA
Kolinsky M P, Rescigno P, Bianchini D, Zafeiriou Z, Mehra N, Mateo J, Michalarea V, Riisnaes R, Crespo M, Figueiredo I, Miranda S, Nava Rodrigues D, Flohr P, Tunariu N, Banerji U, Ruddle R, Sharp A, Welti J, Lambros M, Carreira S, Raynaud F I, Swales K E, Plymate S, Luo J, Tovey H, Porta N, Slade R, Leonard L, Hall E and de Bono J S. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. : Annals of oncology : official journal of the European Society for Medical Oncology. 20210106.